Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs FLOLIPID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
Reduction of elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C in patients with primary hyperlipidemia (Fredrickson type IIa and IIb) or mixed dyslipidemia,Reduction of elevated TG in patients with hypertriglyceridemia (Fredrickson type IV),Treatment of primary dysbetalipoproteinemia (Fredrickson type III) when diet is not sufficient,Reduction of total-C and LDL-C in patients with homozygous familial hypercholesterolemia,Prevention of cardiovascular events in patients with high risk of coronary heart disease
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
More than 99% bound, primarily to albumin.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
For GFR 30 to <60 m L/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 m L/min/1.73 m²: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning).,Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment.,Increased risk of diabetes mellitus: Small increase in fasting glucose and Hb A1c.,Interstitial lung disease: Rare cases reported.,Use with caution in patients with predisposing factors for renal impairment.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Hypersensitivity to any component of Flolipid,Active liver disease or unexplained persistent elevations of serum transaminases,Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone),Concomitant use of gemfibrozil, cyclosporine, or danazol,Pregnancy and breastfeeding,Women of childbearing potential unless using effective contraception
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Grapefruit juice may modestly increase pitavastatin exposure; limit to small amounts (≤8 oz per day). No other significant food interactions; can be taken with or without food. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
Breastfeeding is contraindicated during rosuvastatin therapy. M/P ratio: unknown. Rosuvastatin is excreted in rat milk; human data absent. Potential for serious adverse reactions in nursing infants.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
FLOLIPID should be discontinued upon pregnancy detection. No dose adjustments in pregnancy as use is contraindicated. Pharmacokinetic changes in pregnancy may reduce rosuvastatin exposure, but safety data insufficient to recommend resuming.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Flolipid (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug interactions; monitor for myopathy and hepatotoxicity; avoid in active liver disease; dose adjustment needed with renal impairment (Cr Cl <30 m L/min); no significant food effect, but grapefruit juice may modestly increase exposure; consider in patients with statin intolerance due to fewer CYP-mediated interactions.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
Take Flolipid at the same time each day, with or without food.,Avoid consuming large amounts of grapefruit juice; a small glass (8 oz) is acceptable.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you develop jaundice, dark urine, or abdominal pain (signs of liver problems).,Continue a heart-healthy diet and exercise while taking this medication.,Do not double the dose if you miss one; take the next dose at the usual time.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs FLOLIPID, answered by our medical review team.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. FLOLIPID is a HMG-CoA Reductase Inhibitor (Statin) that works by Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and FLOLIPID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of FLOLIPID is: Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and FLOLIPID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . FLOLIPID is classified as Category C. FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.